Q-omics provides the consensus-scored ZNF714 profile across patient tissues and cancer cell-line models. ZNF714 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF714 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ZNF714 RNA expression shows 19,205 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, BLCA, and UVM as cancer lineages where ZNF714 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF714 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF714 survival associations across molecular data types. ZNF714 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF714 RNA expression–survival associations across cancer types. High ZNF714 expression shows unfavorable associations in MESO, UVM, ACC, UCEC and LIHC, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF714 RNA expression.
This table summarizes ZNF714 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF714. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF714 shows higher tumor expression in BLCA, LIHC, KIRP, BRCA, CHOL and STAD. The BLCA box plot shows higher ZNF714 RNA expression in tumor versus normal tissue (log2 FC = +1.770, t-test p < 0.001).
This table shows molecular features associated with ZNF714 in patient tissues and cancer cell lines. In patient samples, ZNF714 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF714 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
